Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Finance
Milestone payment received, 3Q performance reported
December 26th, 2002
BioSante Pharmaceuticals, Inc., (BISP) announced that during the third quarter it received a clinical milestone payment of $950,000 from Solvay Pharmaceuticals, B.V., the licensee of BioSante's Bio-E/P-Gel topical hormone therapy. The milestone payment was made by Solvay as a result of progress in the development of Bio-E/P-Gel, a topical gel combination of estradiol (the bioidentical human estrogen) and progestogen for treatment of menopausal symptoms in women. The ingredients and route of administration are different from those of the product used in the recently reported Women's Health Initiative (WHI) Study, which consisted of conjugated estrogen and progestin in...
Source: Women's Health Weekly (2002-12-26)
|
